Frank L. Douglas

Douglas published an autobiography in 2018, titled Defining Moments of a Free Man from a Black Stream.

In 2009, Douglas moved to Akron, Ohio, to serve as president and CEO of the Austen BioInnovation Institute. He left the institute at the beginning of 2015.

In 2005, Douglas left Aventis and took a position as a professor of the practice at Massachusetts Institute of Technology, where he was involved in founding the Center for Biomedical Innovation. After 2 years at MIT, he resigned over concerns about institutional racism, particularly regarding the tenure-denial of James Sherley.

Following his fellowship, Douglas took a position as an assistant professor of medicine at the University of Chicago, in which role he remained for 5 years. At this time, he also began work at the pharmaceutical company Ciba-Geigy. In 1992, he moved as an executive vice president to Marion Merrell Dow, where he remained as it was acquired and changed names to Hoechst Marion Roussel, and later to Aventis.

Frank Lennox Douglas (born April 30, 1943) is a Guyanese-American biomedical researcher and business executive.

Douglas was born April 30, 1943 in Georgetown, Guyana. He graduated with a BS in Engineering from Lehigh University in 1966. He went on to a PhD in Physical Chemistry from Cornell University, which he received at the beginning of 1973, with a thesis on chlorophyll-a. After a brief stint working at Xerox, Douglas moved to New York City to pursue a medical degree from the Cornell University Medical School. After finishing the MD, Douglas completed an internship and residency in internal medicine at Johns Hopkins Medical Institution, and a fellowship in neuroendocrinology at the National Institutes of Health.